Renaissance Technologies LLC Purchases 76,921 Shares of Lyell Immunopharma, Inc. $LYEL

Renaissance Technologies LLC increased its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 194.8% in the 1st quarter, HoldingsChannel reports. The fund owned 116,411 shares of the company’s stock after purchasing an additional 76,921 shares during the period. Renaissance Technologies LLC’s holdings in Lyell Immunopharma were worth $2,335,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in LYEL. GSK plc bought a new stake in Lyell Immunopharma in the 4th quarter valued at about $46,560,000. MWG Caph Ltd bought a new position in Lyell Immunopharma during the fourth quarter worth about $31,030,000. ARCH Venture Management LLC increased its stake in shares of Lyell Immunopharma by 51.5% in the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after purchasing an additional 938,438 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Lyell Immunopharma by 76.0% in the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $14.33 on Tuesday. Lyell Immunopharma, Inc. has a 1 year low of $9.28 and a 1 year high of $45.00. The stock has a market capitalization of $351.08 million, a PE ratio of -1.12 and a beta of -0.04. The company’s 50 day simple moving average is $13.39 and its two-hundred day simple moving average is $18.90.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating the consensus estimate of ($1.94) by $0.02. The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 87.60%. On average, research analysts anticipate that Lyell Immunopharma, Inc. will post -7.48 EPS for the current year.

Analyst Upgrades and Downgrades

LYEL has been the topic of a number of recent research reports. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 price objective on shares of Lyell Immunopharma in a research note on Monday, June 15th. Citizens Jmp restated a “market outperform” rating and set a $34.00 target price on shares of Lyell Immunopharma in a research report on Monday, June 15th. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.